Kürşat ALTINBAŞ, Tuğba İZCİ DURAN, Melih PAMUKCU, Hasan ULUSOY

Investigation of the correlation between mood disorder symptoms and disease activity and functional status in rheumatoid arthritis patients

Background/aim: To investigate the correlation between depressive-anxiety symptoms, mixed features, disease activity, and functional status in patients with rheumatoid arthritis (RA) in the light of the shared underlying etiology in both disorders. Materials and methods: The study included 556 patients with RA. RA disease activity was measured using the Disease Activity Score 28-joint count C reactive protein (DAS28-CRP), and the patients were evaluated by a Health Assessment Questionnaire (HAQ). The Hospital Anxiety and Depression Scale (HADS), Mood Disorder Questionnaire (MDQ), and Modified Hypomania Checklist (mHCL) were used to evaluate the mixed depression and bipolarity status of the patients. Results: Of the patients, 430 (77.3%) were female and 126 (22.7%) were male. The median age was 57 years, the median HAQ score was 0.55 points, and the median DAS28-CRP score was 4.1 points. The evaluation of the patients by DAS28-CRP revealed that 58.5% of the patients had moderate and severe disease activity, while only 23.4% of them were in remission. The group using the combination of synthetic disease-modifying anti-rheumatic drugs (sDMARD) and steroid therapy had significantly higher HAD-depression, HADanxiety, mHCL, DAS28-CRP, HAQ, and MDQ scores than the group using sDMARD alone. The grouping of the patients based on the DAS28-CRP cut-off scores showed that the patients with moderate and severe disease activity had significantly higher HADS, mHCL, MDQ scores than those in remission and those with mild disease activity (p < 0.001). Conclusion: Disease severity and functional status in RA can be affected by comorbid anxiety-depressive and mixed symptoms. Therefore, clinicians should consider screening the depressive-anxiety and mixed mood symptoms of RA patients. Moreover, patients who use steroid therapy are more susceptible to mood symptoms (anxiety, depression, bipolarity), which should also be considered during the follow-up of patients.Key words: Arthritis, rheumatoid, bipolar disorder/psychology, depression/psychology, prevalence

PDF

___

1. Beşirli A, Alptekin J, Kaymak D, Özer Ö A. The relationship between anxiety, depression, suicidal ideation and quality of life in patients with rheumatoid arthritis. The Psychiatric Quarterly 2020;91(1):53-64. doi: 10.1007/s11126-019-09680-x
2. Dougados M, Soubrier M, Antunez A, Balint P, Balsa A et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, crosssectional study (COMORA). Annals of The Rheumatic Diseases 2014;73(1):62-68. doi: 10.1136/annrheumdis-2013-204223
3. VanDyke MM, Parker JC, Smarr KL, Hewett JE, Johnson GE et al. Anxiety in rheumatoid arthritis. Arthritis and Rheumatism 2004 June 15;51(3):408-412. doi: 10.1002/art.20474
4. Kivimäki M, Shipley MJ, Batty GD, Hamer M, Akbaraly TN et al. Long-term inflammation increases risk of common mental disorder: a cohort study. Molecular Psychiatry 2014;19(2):149- 150. doi: 10.1038/mp.2013.35
5. Calabrese LH. Rheumatoid arthritis and primary care: the case for early diagnosis and treatment. The Journal of the American Osteopathic Association 1999;99(6):313-321. doi: 10.7556/ jaoa.1999.99.6.313
6. Derksen V, Huizinga TWJ, van der Woude D. The role of autoantibodies in the pathophysiology of rheumatoid arthritis. Seminars in Immunopathology 2017;39(4):437-446. doi: 10.1007/s00281-017-0627-z
7. Volkov M, van Schie KA. Autoantibodies and B Cells: The ABC of rheumatoid arthritis pathophysiology. Immunological Reviews 2020;294(1):148-163. doi: 10.1111/imr.12829
8. Najjar S, Pearlman DM, Alper K, Najjar A, Devinsky O. Neuroinflammation and psychiatric illness. Journal of Neuroinflammation 2013;1;10:43. doi: 10.1186/1742-2094-10-43
9. Young LD. Psychological factors in rheumatoid arthritis. Journal of Consulting and Clinical Psychology 1992;60(4):619-627. doi: 10.1037//0022-006x.60.4.619
10. Sharpe L, Sensky T, Timberlake N, Ryan B, Brewin CR et al. A blind, randomized, controlled trial of cognitive-behavioural intervention for patients with recent onset rheumatoid arthritis: preventing psychological and physical morbidity. Pain 2001;89(2-3):275-283. doi: 10.1016/s0304-3959(00)00379-1
11. Pacchiarotti I, Kotzalidis GD, Murru A, Mazzarini L, Rapinesi C et al. Mixed features in depression: The unmet needs of diagnostic and statistical manual of mental disorders fifth edition. The Psychiatric Clinics of North America 2020;43(1):59-68. doi: 10.1016/j.psc.2019.10.006
12. Taş H, Altinbaş K. Comparison of the emotion regulation and temperament characteristics between depressive patients with and without mixed features. Archives of Neuropsychiatry 2019;12;57(1):27-32. doi: 10.29399/npa.23610
13. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis and Rheumatism 1988;31(3):315-324. doi: 10.1002/art.1780310302
14. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatrica Scandinavica 1983;67(6):361-370. doi: 10.1111/j.1600-0447.1983.tb09716.x
15. Aydemir O. Validity and reliability of Turkish version of Hospital Anxiety and Depression Scale. Turkish Journal of Psychiatry 1997;8(4):280-287.
16. Altinbas K, Ozerdem A, Prieto ML, Fuentes ME, Yalin N et al. A multinational study to pilot the modified Hypomania Checklist (mHCL) in the assessment of mixed depression. Journal of Affective Disorders 2014;152-154:478-82. doi: 10.1016/j. jad.2013.07.032
17. Hirschfeld RM, Holzer C, Calabrese JR, Weissman M, Reed M et al. Validity of the mood disorder questionnaire: a general population study. The American Journal of Psychiatry 2003 ;160(1):178-180. doi: 10.1176/appi.ajp.160.1.178
18. Konuk N, Kiran S, Tamam L, Karaahmet E, Aydin H et al. Validation of the Turkish version of the mood disorder questionnaire for screening bipolar disorders. Turkish Journal of Psychiatry 2007 Summer;18(2):147-154
19. Pereira AM, Tiemensma J, Romijn JA. Neuropsychiatric disorders in Cushing’s syndrome. Neuroendocrinology 2010;92 Suppl 1:65-70. doi: 10.1159/000314317
20. Lok EY, Mok CC, Cheng CW, Cheung EF. Prevalence and determinants of psychiatric disorders in patients with rheumatoid arthritis. Psychosomatics 2010 JulyAugust;51(4):338-338.e8. doi: 10.1176/appi.psy.51.4.338
21. Isik A, Koca SS, Ozturk A, Mermi O. Anxiety and depression in patients with rheumatoid arthritis. Clinical Rheumatology 2007;26(6):872-878. doi: 10.1007/s10067-006-0407-y
22. Matcham F, Rayner L, Steer S, Hotopf M. The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology (Oxford) 2013;52(12):2136- 2148. doi: 10.1093/rheumatology/ket169
23. Hsu C-C, Chen S-C, Liu C-J, Lu T, Shen C-C et al. Rheumatoid arthritis and the risk of bipolar disorder: a nationwide population-based study. PLoS One 2014;17;9(9):e107512. doi: 10.1371/journal.pone.0107512
24. Farhi A, Cohen AD, Shovman O, Comaneshter D, Amital H et al. Bipolar disorder associated with rheumatoid arthritis: A casecontrol study. Journal of Affective Disorders 2016;1;189:287- 289. doi: 10.1016/j.jad.2015.09.058
25. Charoenngam N, Ponvilawan B, Ungprasert P. Patients with rheumatoid arthritis have a higher risk of bipolar disorder: A systematic review and meta-analysis. Psychiatry Research 2019;282:112484. doi: 10.1016/j.psychres.2019.112484
26. Imperatori C, Bianciardi E, Niolu C, Fabbricatore M, Gentileschi P et al. The Symptom-Checklist-K-9 (SCL-K-9) discriminates between overweight/obese patients with and without significant binge eating pathology: Psychometric properties of an Italian version. Nutrients 2020 ;12(3), 674. https://doi. org/10.3390/nu12030674
27. Firestein GS, McInnes IB. Immunopathogenesis of rheumatoid arthritis. Immunity 2017 ;21;46(2):183-196. doi: 10.1016/j. immuni.2017.02.006
28. Goldsmith DR, Rapaport MH, Miller BJ. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Molecular Psychiatry 2016;21(12):1696-1709. doi: 10.1038/mp.2016.3
29. Köhler CA, Freitas TH, Maes M, de Andrade NQ, Liu CS et al. Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies. Acta Psychiatrica Scandinavica 2017;135(5):373-387. doi: 10.1111/acps.12698
30. Haapakoski R, Mathieu J, Ebmeier KP, Alenius H, Kivimäki M. Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder. Brain, Behavior, and Immunity 2015;49:206-215. doi: 10.1016/j.bbi.2015.06.001
31. Dantzer R. Cytokine-induced sickness behaviour: a neuroimmune response to activation of innate immunity. European Journal of Pharmacology 2004;1;500(1-3):399-411. doi: 10.1016/j. ejphar.2004.07.040
32. Chimenti MS, Fonti GL, Conigliaro P, Triggianese P, Bianciardi E et al. The burden of depressive disorders in musculoskeletal diseases: is there an association between mood and inflammation? Annals of General Psychiatry 2021;4;20(1):1. doi: 10.1186/s12991-020-00322-2
33. Stertz L, Magalhães PV, Kapczinski F. Is bipolar disorder an inflammatory condition? The relevance of microglial activation. Current Opinion in Psychiatry 2013;26(1):19-26. doi: 10.1097/YCO.0b013e32835aa4b4
34. Rege S, Hodgkinson SJ. Immune dysregulation and autoimmunity in bipolar disorder: Synthesis of the evidence and its clinical application. The Australian and New Zealand Journal of Psychiatry 2013;47(12):1136-1151. doi: 10.1177/0004867413499077
35. Munkholm K, Vinberg M, Vedel Kessing L. Cytokines in bipolar disorder: a systematic review and meta-analysis. Journal of Affective Disorders 2013;10;144(1-2):16-27. doi: 10.1016/j. jad.2012.06.010
36. Covic T, Cumming SR, Pallant JF, Manolios N, Emery P et al. Depression and anxiety in patients with rheumatoid arthritis: prevalence rates based on a comparison of the depression, anxiety and stress scale (DASS) and the hospital, anxiety and depression scale (HADS). BMC Psychiatry 2012;24;12:6. doi: 10.1186/1471-244X-12-6
37. Sturgeon JA, Finan PH, Zautra AJ. Affective disturbance in rheumatoid arthritis: psychological and disease-related pathways. Nature Reviews Rheumatology 2016;12(9):532-542. doi: 10.1038/nrrheum.2016.112
38. Michelsen B, Kristianslund EK, Sexton J, Hammer HB, Fagerli KM et al. Do depression and anxiety reduce the likelihood of remission in rheumatoid arthritis and psoriatic arthritis? Data from the prospective multicentre NOR-DMARD study. Annals of the Rheumatic Diseases 2017;76(11):1906-1910. doi: 10.1136/annrheumdis-2017-211284
39. Lee CH, Giuliani F. The role of inflammation in depression and fatigue. Frontiers in immunology 2019;19;10:1696. doi: 10.3389/fimmu.2019.01696
40. Margaretten M, Julian L, Katz P, Yelin E. Depression in patients with rheumatoid arthritis: description, causes and mechanisms. International Journal of Clinical Rheumatology 2011;6(6):617- 623. doi: 10.2217/IJR.11.6
41. Rathbun AM, Reed GW, Harrold LR. The temporal relationship between depression and rheumatoid arthritis disease activity, treatment persistence and response: a systematic review. Rheumatology (Oxford) 2013;52(10):1785-1794. doi: 10.1093/ rheumatology/kes356
42. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Archives of Internal Medicine 2000;24;160(14):2101-2107. doi: 10.1001/archinte.160.14.2101
43. Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003; 16;108(24):2957- 2963. doi: 10.1161/01.CIR.0000099844.31524.05
44. Timonen M, Viilo K, Hakko H, Särkioja T, Ylikulju M et al. Suicides in persons suffering from rheumatoid arthritis. Rheumatology (Oxford) 2003;42(2):287-291. doi: 10.1093/ rheumatology/keg082
45. Ang DC, Choi H, Kroenke K, Wolfe F. Comorbid depression is an independent risk factor for mortality in patients with rheumatoid arthritis. The Journal of Rheumatology 2005;32(6):1013-1019
46. Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: A review. JAMA. 2018;2;320(13):1360-1372. doi: 10.1001/jama.2018.13103
47. Brown ES, Chandler PA. Mood and cognitive changes during systemic corticosteroid therapy. Primary Care Companion to the Journal of Clinical Psychiatry 2001;3(1):17-21. doi: 10.4088/pcc.v03n0104
48. Naber D, Sand P, Heigl B. Psychopathological and neuropsychological effects of 8-days’ corticosteroid treatment. A prospective study. Psychoneuroendocrinology 1996;21(1):25-31. doi: 10.1016/0306-4530(95)00031-3
49. Brown ES. Effects of glucocorticoids on mood, memory, and the hippocampus. Treatment and preventive therapy. Annals of the New York Academy of Sciences 2009;1179:41-55. doi: 10.1111/j.1749-6632.2009.04981.x
50. Gilad GM, Rabey JM, Gilad VH. Presynaptic effects of glucocorticoids on dopaminergic and cholinergic synaptosomes. Implications for rapid endocrine-neural interactions in stress. Life Sciences 1987;22;40(25):2401-2408. doi: 10.1016/0024-3205(87)90754-5
51. Beshay H, Pumariega AJ. Sertraline treatment of mood disorder associated with prednisone: a case report. Journal of Child and Adolescent Psychopharmacology 1998;8(3):187-193. doi: 10.1089/cap.1998.8.187